Travere halts Phase 3 inherited disease trial due to manufacturing scale-up issue
Travere Therapeutics said there is a “voluntary pause” in recruitment to its Phase 3 study in a rare, inherited disorder due to issues in scaling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
